Form 4: Pluri Director Eitan Ajchenbaum Granted 11,685 RSUs

Pluri Inc. Director Eitan Ajchenbaum received a grant of 11,685 restricted stock units under the company's 2019 Equity Compensation Plan.

Summary

• Eitan Ajchenbaum, a Director of Pluri Inc. (PLUR), was granted 11,685 Restricted Stock Units (RSUs).
• The RSUs were approved for grant by the Board of Directors on November 12, 2025, under the Company's 2019 Equity Compensation Plan.
• The grant price for these RSUs was $0.
• The RSUs will vest over a three-year period: 50% will vest ratably on a quarterly basis during the first year, 25% during the second year, and the remaining 25% during the third year following the grant date.
• Following this transaction, Eitan Ajchenbaum beneficially owns 11,685 shares of Common Stock directly.

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units (RSUs) to a director is a routine compensation event that aligns the director's interests with shareholders, generally viewed as neutral to slightly positive for corporate governance.

Positives

• The grant of Restricted Stock Units (RSUs) aligns the director's long-term interests with those of the shareholders, incentivizing sustained performance.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, indicating a structured approach to compensation.

Future Outlook

The Restricted Stock Units (RSUs) are subject to a three-year vesting schedule, with 50% vesting in the first year, 25% in the second, and 25% in the third, indicating a future increase in the director's beneficial ownership as the units vest.

Industry Context

This grant of Restricted Stock Units (RSUs) to a director is a common practice in the biotechnology and broader corporate sectors for executive and director compensation, aiming to align their long-term interests with those of shareholders. It reflects a standard approach to incentivizing leadership through equity.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of director compensation is a widely adopted practice across various industries, including biotechnology.
• Companies like Gilead Sciences, Amgen, and Regeneron Pharmaceuticals frequently utilize similar equity-based compensation plans for their directors and executives to foster long-term commitment and performance alignment.
• While specific grant sizes vary based on company size, director responsibilities, and overall compensation philosophy, the mechanism of granting RSUs with a multi-year vesting schedule is a global benchmark for corporate governance and incentive structures.

Corporate Governance

Related Party Transactions

• Grant of 11,685 Restricted Stock Units (RSUs) to Eitan Ajchenbaum, a Director of Pluri Inc., under the Company's 2019 Equity Compensation Plan.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units (RSUs) will vest over a three-year period, with quarterly vesting increments, starting from the grant date of November 12, 2025.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and aligns management interests with shareholders. It does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate as it maintains the status quo.

Keywords

Pluri Inc., PLUR, Form 4, SEC filing, insider transaction, restricted stock units, RSU grant, equity compensation, director compensation, Eitan Ajchenbaum